SilkRoad Technology co-founder Brian Platz has turned his attention to blockchain, with Fluree, a new Public Benefit Corporation that has introduced a scalable blockchain database for decentralized applications. Fluree is not healthcare specific, but there is a lot of potential for blockchain.
In this podcast interview we covered the following:
(0:10) What is a scalable blockchain database and why is it important?
(1:58) What are some of the most pressing database needs in healthcare? How different are they from the issues faced by other industries?
(3:07) What are some of the healthcare use cases for Fluree?
(5:15) You mention transparency and consensus as key attributes of block chain. Does that contradict healthcare’s needs for privacy and security?
(6:35) Who will leverage the technology in healthcare? Who is likely to be left behind?
(7:46) What impact, if any, will healthcare consumers and patients see as a result of Fluree?
(8:51) Why is Fluree organized as a Public Benefit Corporation?
Nutrition is important for everyone, but for cancer patients it’s especially critical. Many cancer patients struggle with appetite and weight loss; nutrition challenges affect patients’ ability to tolerate treatment and contribute to mortality.
Savor Health provides oncology-related nutritional solutions. I spoke with founder and CEO Susan Bratton to learn more.
(0:14) Why is nutrition so important for cancer patients?
(1:30) How common is malnutrition among cancer patients?
(2:12) How well understood is this problem? Is awareness increasing?
(5:24) Do patients understand just how serious the consequences of malnutrition are, beyond a general awareness of the importance of nutrition?
(6:32) How do nutritional issues vary by type of cancer?
(9:35) How did you become interested in this field?
(12:13) What are some of the approaches being used to address nutrition among cancer patients?
(14:15) Is there an overlap between nutritional counseling and behavioral health? Is depression taken into account?
Murali Minnah, co-founder and chief strategy officer of Wired Informatics
Natural language processing (NLP) is a fascinating segment of Artificial Intelligence that draws on a variety of emerging scientific fields. Wired Informatics is developing and commercializing NLP within the healthcare industry.
I met co-founder and chief strategy officer, Murali Minnah last year and we have been exploring applications for NLP within Health Business Group’s client base. I admire the company and its approach, so asked Murali to share his insights in this podcast:
(0:11) You are involved with a lot of the hot buzzwords: big data, natural language processing, and machine learning. What do those words actually mean to you?
(4:59) Are there aspects of healthcare that lend themselves well to natural language processing?
(7:18) How well does NLP actually work today? What’s the trajectory for its development?
(8:42) How do you work with a technology that is good and improving but not perfect? In healthcare it seems we’d be concerned about something that isn’t perfectly accurate.
(10:59) If you do get to 100 percent accuracy, how do you contend with problems in the underlying data?
(12:50) You mentioned operational use cases as the first places to start. What are some of the most compelling use cases today and down the road?
(15:35) Where is your company getting traction? What use cases? What customers?
Innovative Israeli technology companies have a huge impact around the world. Now, more of the country’s entrepreneurs are turning to connected health. mHealth Israel is at the center of this surge. Its upcoming mHealth Israel conference on September 14 will be the culmination of a nationwide week of activities.
I had planned to speak at the conference, but sadly won’t make it to Jerusalem this time around.
Levy shared his perspectives on mHealth in Israel and provided background on the upcoming mHealth conference.
(0:13) What’s the state of digital health in Israel? How does it differ from markets in the US and Europe?
(1:58) Israel is a small market and doesn’t trade much with its neighbors. Are most of these companies focused locally or are they looking at external markets?
(3:09) Describe the ecosystem. What is the typical interaction between the startup companies, hospitals and larger companies?
(7:10) What are some of the major themes you are seeing in health startups this year? Is it a change from the last couple years?
It takes an average of 24 days for a new patient to get an appointment with a doctor, up 30 percent since 2014. In Boston, it’s 52 days! Physician schedules are full, and yet a significant percentage of appointments are canceled or patients just don’t show up –costing doctors billions in revenue and depriving needy patients of appointments.
These two things are related: with such a long wait the patient may either be cured on her own, go to the ED, die, or just forget about the visit.
Patrick Rudolph saw an opportunity to do something about this problem and started QueueDr to simply and automatically offer patients a chance to fill those open slots. You can listen to him explain in our podcast:
(0:10) What problem are you addressing?
(0:58) Why do you think the problem is getting worse?
(2:25) Bad technology is a problem. What do you mean that your technology doesn’t require anything of the user?
(3:44) What does it look like from the patient standpoint?
(4:54) One of your customers says your product works “too well.” What is he talking about?
(5:58) Do you think this cancellation issue is a standalone solution or should it be a feature in a broader system?
(8:01) You’re not the first one to address scheduling and cancellation as a challenge. How do you compare with other approaches?
(9:46) How would QueueDr work with a policy like charging patients who don’t show up or introducing an open access schedule?
(11:58) Where will the company be five years from now?
Medial EarlySign analyzes standard EHR data to identify individuals at high risk for disease. The company’s first solution, ColonFlag uses longitudinal blood test data to identify patients who are at high risk for colorectal cancer.
I spoke recently with Medial executive Tomer Amit, who filled me in on the company’s approach and explained why the company has been named a Cool Vendor in AI by Gartner.
(0:15) What unmet need are you serving?
(1:05) You talk about using data that’s already available. What kind of data?
(3:02) When you mention “historical data” are you talking about longitudinal data for an individual patient or aggregated data for a population?
(4:18) Why is colorectal cancer an initial focus for the company, with your ColonFlag solution?
(5:13) Does ColonFlag replace colonoscopy or encourage someone to get one if they have an indicator that they are at greater risk?
(6:38) I see how it could help an individual. Would it actually help at the population level?
(7:45) You started in Israel and the EU, which have strong longitudinal medical records. Can the approach be applied in the US where that’s not the case?
(10:41) You have run your tests in different places around the world. Does the model differ by population or is there a universal algorithm?
(12:10) How do you protect your intellectual property? Once you are out there, are there just rules of thumb people can use instead of working with you?
(13:14) What traction have you gained with customers or partners? What industry recognition have you received?
(14:45) Are there other domains you are investigating beyond colon cancer? Other data beyond blood tests?
(15:58) What’s your 5-10 year vision of what’s possible and what Medial’s role will be?